Swiss National Bank Purchases 4,900 Shares of Natera, Inc. (NASDAQ:NTRA)

Swiss National Bank increased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 2.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 232,800 shares of the medical research company’s stock after acquiring an additional 4,900 shares during the period. Swiss National Bank’s holdings in Natera were worth $36,852,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cerity Partners LLC increased its holdings in Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after acquiring an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Natera during the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. bought a new stake in Natera during the 4th quarter worth approximately $573,000. Alpha DNA Investment Management LLC bought a new stake in Natera during the 3rd quarter worth approximately $505,000. Finally, First Turn Management LLC bought a new stake in Natera during the 3rd quarter worth approximately $19,760,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NTRA shares. Canaccord Genuity Group restated a “buy” rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Piper Sandler raised their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Guggenheim raised their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Finally, StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Price Performance

Shares of Natera stock opened at $148.22 on Monday. The firm has a market cap of $20.04 billion, a PE ratio of -84.22 and a beta of 1.80. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s fifty day simple moving average is $163.70 and its two-hundred day simple moving average is $148.83.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares of the company’s stock, valued at approximately $29,160,963.60. The trade was a 30.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the sale, the director now directly owns 9,704 shares in the company, valued at $1,433,183.76. The trade was a 29.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 298,946 shares of company stock valued at $47,803,462 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.